Product
Supplier
Encyclopedia
Inquiry
Home > News > Company News > Sun Pharma Receives EIR for Halol Facility

Sun Pharma Receives EIR for Halol Facility

Chemical Weekly 2018-06-28

Sun Pharmaceutical Industries Ltd. has announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat) during the period February 12-23, 2018. The agency concluded that the inspection is now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed. “This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and 24x7 cGMP compliance at all our manufacturing facilities globally,” Mr. Dilip Shanghvi, Managing Director, Sun Pharma said on the development.

Dilip_Shanghvi

Dilip Shanghvi

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Looking for chemical products? Let suppliers reach out to you!

Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.